Patents by Inventor Daniel Teper

Daniel Teper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240199759
    Abstract: This disclosure provides bispecific antibody molecules that specifically bind to NKp46 and Glypican 3 (GPC3). The disclosure further relates to combination therapies comprising the bispecific antibody molecules. The bispecific antibody molecules can be used to treat, prevent and/or diagnose cancer or infectious conditions or disorders associated with cells expressing NKp46 and/or GPC3.
    Type: Application
    Filed: April 5, 2022
    Publication date: June 20, 2024
    Applicant: CYTOVIA THERAPEUTICS, LLC.
    Inventors: Jean KADOUCHE, Wei LI, Daniel TEPER
  • Publication number: 20240199756
    Abstract: This disclosure provides bispecific antibody molecules that specifically bind to NKp46 and CD38. The disclosure further relates to combination therapies comprising the bispecific antibody molecules. The bispecific antibody molecules can be used to treat, prevent and/or diagnose cancer or infectious conditions or disorders associated with cells expressing NKp46 and/or CD38.
    Type: Application
    Filed: April 5, 2022
    Publication date: June 20, 2024
    Applicant: CYTOVIA THERAPEUTICS, LLC.
    Inventors: Jean KADOUCHE, Wei LI, Daniel TEPER
  • Publication number: 20170247442
    Abstract: The present invention provides use of one or more complementary determining regions (CDRs) of the CAT-212-213 VH and/or VL domains in non-native antibody framework regions, or, alternatively, the whole VH, VL, or CAT-212 antibody, in treating inflammatory diseases in a subject, such as inflammatory bowel disease.
    Type: Application
    Filed: November 10, 2016
    Publication date: August 31, 2017
    Inventor: Daniel TEPER
  • Publication number: 20140271666
    Abstract: The present invention provides use of one or more complementary determining regions (CDRs) of the CAT-212-213 VH and/or VL domains in non-native antibody framework regions, or, alternatively, the whole VH, VL, or CAT-212 antibody, in treating inflammatory diseases in a subject, such as inflammatory bowel disease.
    Type: Application
    Filed: April 17, 2013
    Publication date: September 18, 2014
    Inventor: DANIEL TEPER
  • Publication number: 20140271663
    Abstract: The present invention provides use of one or more complementary determining regions (CDRs) of the CAT-212-213 VH and/or VL domains in non-native antibody framework regions, or, alternatively, the whole VH, VL, or CAT-212 antibody, in treating inflammatory diseases in a subject, such as inflammatory bowel disease.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: Immune Pharmaceuticals Ltd.
    Inventor: Daniel Teper